ArticleNature2024
Computationally restoring the potency of a clinical antibody against Omicron.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- R1-32-like public antibodies acquire tolerance to SARS-CoV-2 antigenic drift through somatic hypermutation.PLoS biology · 2026Article
- Artificial intelligence in drug discovery - what it is, where we stand and the path forward.Nature reviews. Drug discovery · 2026Review
- Structure-Guided Design of Therapeutic Antibodies Targeting SARS-CoV-2 Omicron Variants.Research square · 2026Article
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Reverse vaccinology 3.0.Nature reviews. Microbiology · 2026Article
- Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape.PLoS pathogens · 2026Article
- How new approach methods are reshaping virology research.Journal of virology · 2026Review
- Review
- Artificial intelligence directed computational protein design: lessons from COVID-19 for pandemic-ready vaccines and antibody therapeutics.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Review
- Innovation in active and passive immunisation of people who are immunocompromised: a call to action.The Lancet. Infectious diseases · 2026Review
- Applications of Pseudoviruses Bearing Glycoproteins of SARS-CoV-2 and Influenza Virus.Advances in experimental medicine and biology · 2026Review
- Article
- Optimizing the breadth of SARS-CoV-2-neutralizing antibodies in vivo and in silico.Human vaccines & immunotherapeutics · 2025Review
- Article
- Article
- Article
- A comprehensive strategy for pandemic preparedness with neutralizing monoclonal antibodies.mAbs · 2025Article
- RESP2: An Uncertainty Aware Multi-Target Multi-Property Optimization AI Pipeline for Antibody Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Significantly enhancing human antibody affinity via deep learning and computational biology-guided single-point mutations.Briefings in bioinformatics · 2025Article
- Advances in Techniques for the Structure and Functional Optimization of Therapeutic Monoclonal Antibodies.Biomedicines · 2025Review
Corrections and comments
- Update of
Authors and funding
44 authors.
Thomas A DesautelsComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.ORCID 0000-0001-6853-981X
Kathryn T ArrildtBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.ORCID 0000-0001-6329-6214
Adam T ZemlaGlobal Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.ORCID 0000-0003-0504-8647
Edmond Y LauBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Fangqiang ZhuBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Dante RicciBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Stephanie CroninVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Seth J ZostVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-6712-5076
Elad BinshteinVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-2745-104X
Suzanne M ScheafferDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Bernadeta DadonaiteBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-0908-6982
Brenden K PetersenComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Taylor B EngdahlVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-6280-4405
Elaine ChenVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Laura S HandalVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-8658-4411
Lynn HallVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
John W GoforthGlobal Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Denis VashchenkoApplications Simulations and Quality Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Sam NguyenComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Dina R WeilhammerBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Jacky Kai-Yin LoBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Bonnee RubinfeldBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Edwin A SaadaBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Tracy WeisenbergerBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Tek-Hyung LeeBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Bradley WhitenerDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-6652-0701
James B CaseDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-7331-5511
Alexander LaddComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Mary S SilvaGlobal Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Rebecca M HaluskaApplications Simulations and Quality Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Emilia A GrzesiakGlobal Security Computing Applications Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Christopher G EarnhartJoint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, US Department of Defense, Frederick, MD, USA.
Svetlana HopkinsJoint Rsearch and Development Inc., Stafford, VA, USA.
Thomas W BatesComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Larissa B ThackrayDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-9380-6569
Brent W SegelkeBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Tri-lab COVID-19 Consortium
Antonietta Maria LilloLos Alamos National Laboratory, Bioscience Division, Los Alamos, NM, USA.
Shivshankar SundaramCenter for Bioengineering, Lawrence Livermore National Laboratory, Livermore, CA, USA.
Jesse D BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-1267-3408
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-8791-3165
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-0049-1079
Robert H CarnahanVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-5230-1532
Daniel M FaissolComputational Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, USA. faissol1@llnl.gov.ORCID 0000-0001-6965-983X
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MB-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION: Modification for SARS-CoV2 Research75N93019C00074 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2019 to 2024
$10.2MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MProspectively characterizing the functional and antigenic effects of mutations to viral entry proteinsR01AI141707 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2018 to 2022
$2.1MNIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93019C00074NIAID NIH HHS R01 AI141707NIAID NIH HHS R01 AI157155
Abstract
The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs
Indexed as
Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralComputer SimulationDrug DesignSARS-CoV-2AnimalsAntigenic Drift and ShiftCOVID-19DNA Mutational AnalysisFemaleHumansMiceMutationNeutralization TestsSpike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralcilgavimabCOV2-2130Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.